San Diego – October 6, 2016 – Cooley advised TRACON Pharmaceuticals on its strategic licensing collaboration with Janssen Pharmaceutical for two novel oncology assets and on its $5 million equity investment from Johnson & Johnson Innovation – JJDC.

The transaction grants TRACON the rights to develop two Janssen oncology programs: TRC253, a novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, intended for the treatment of men with prostate cancer; and TRC694, a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase, intended for the treatment of patients with hematologic malignancies including myeloma.

TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration and fibrotic diseases. Janssen is a pharmaceutical company headquartered in Belgium.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.